Alphabet revenue misses expectations, Robinhood Markets says Super Bowl bets are off, and more news to start your day.

We disagree as this is an AI Arms Race and Alphabet is making the right moves at the right time. While this quarter was not a ...

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Eli Lilly has called on financial regulators ... The issue was also alluded to by Lilly’s chief financial officer, Anat Ashkenazi, on the company’s fourth-quarter results call yesterday ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...